Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) EBT (2016 - 2025)

Spero Therapeutics' EBT history spans 10 years, with the latest figure at $31.8 million for Q4 2025.

  • For Q4 2025, EBT rose 299.86% year-over-year to $31.8 million; the TTM value through Dec 2025 reached $8.8 million, up 113.83%, while the annual FY2025 figure was $8.8 million, 113.83% up from the prior year.
  • EBT reached $31.8 million in Q4 2025 per SPRO's latest filing, up from -$7.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $52.6 million in Q4 2023 to a low of -$30.1 million in Q1 2022.
  • Average EBT over 5 years is -$7.6 million, with a median of -$13.6 million recorded in 2023.
  • Peak YoY movement for EBT: plummeted 1669.41% in 2024, then skyrocketed 299.86% in 2025.
  • A 5-year view of EBT shows it stood at -$27.4 million in 2021, then surged by 215.6% to $31.7 million in 2022, then soared by 65.98% to $52.6 million in 2023, then crashed by 130.22% to -$15.9 million in 2024, then surged by 299.86% to $31.8 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's EBT are $31.8 million (Q4 2025), -$7.4 million (Q3 2025), and -$1.7 million (Q2 2025).